Domov › Prekomerna telesna teža › New York

Klinične študije za Prekomerna telesna teža v New York

45 študij za Prekomerna telesna teža išče udeležence na lokacijah v New York.

Mesta v New York

Uradno besedilo študije (angleško)

Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities

Rochester Clinical Research /ID# 282484, Rochester

Vključevanje udeležencevFaza 2

Starost 18–75 · Vsi spoli · Posodobljeno 2. okt. 2026 · NCT07752979

Hydration Intervention to Decrease Side Effects Associated With GLP - 1 RA Therapy

State University of New York at Buffalo, South Campus, Buffalo

Vključevanje udeležencev

Starost 18–60 · Vsi spoli · Posodobljeno 2. okt. 2026 · NCT07641361

Comparing the Efficacy and Safety of the EndoZip System and Apollo ESG in Obese Patients

Weill Cornell -1300 York Avenue, New York
Lenox Hill Hospital | Northwell Health, New York

Vključevanje udeležencev

Starost 21–65 · Vsi spoli · Posodobljeno 1. okt. 2026 · NCT07090005

AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight

Southgate Medical Group, LLP, West Seneca

Vključevanje udeležencevFaza 3

Starost 18 in več · Vsi spoli · Posodobljeno 30. sep. 2026 · NCT07533175

A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight

UBMD Physicians Group - Pediatrics - Conventus, Buffalo
SUNY Upstate Medical Univ - Syracuse, Syracuse
Advantage Clinical Trials, The Bronx

Vključevanje udeležencevFaza 3

Starost 8–18 · Vsi spoli · Posodobljeno 30. sep. 2026 · NCT07253285

Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes

Rochester Clinical Research, Rochester

Vključevanje udeležencevFaza 2

Starost 18 in več · Vsi spoli · Posodobljeno 29. sep. 2026 · NCT07685808

Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss

ALSA Research-Manhattan, New York

Vključevanje udeležencevFaza 2

Starost 18–75 · Vsi spoli · Posodobljeno 28. sep. 2026 · NCT07837973

AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight

Comprehensive Weight Ctrl Prog, New York

Vključevanje udeležencevFaza 3

Starost 18 in več · Vsi spoli · Posodobljeno 28. sep. 2026 · NCT07720271

A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide

Ichor Research, Syracuse
Southgate Medical Group, LLP, West Seneca

Vključevanje udeležencevFaza 3

Starost 18 in več · Vsi spoli · Posodobljeno 28. sep. 2026 · NCT07668414

A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity

Drug Trials America, Hartsdale
NYC Research INC, Long Island City
Rochester Clinical Research, LLC, Rochester

Vključevanje udeležencevFaza 3

Starost 18 in več · Vsi spoli · Posodobljeno 28. sep. 2026 · NCT07794579

A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity

Weill Cornell Medicine - Comprehensive Weight Control Center, New York
Rochester Clinical Research, LLC, Rochester

Vključevanje udeležencevFaza 3

Starost 18 in več · Vsi spoli · Posodobljeno 28. sep. 2026 · NCT07595549

Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

New York Gastroenterology Associates, New York
Care Access - Yonkers, Yonkers

Vključevanje udeležencevFaza 3

Starost 18–70 · Vsi spoli · Posodobljeno 24. sep. 2026 · NCT06937099

A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

UBMD Pediatrics, Buffalo

Vključevanje udeležencevFaza 3

Starost 6–17 · Vsi spoli · Posodobljeno 24. sep. 2026 · NCT06672549

Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

Icahn School of Medicine at Mount Sinai, New York
New York Gastroenterology Associates, New York
Care Access - Yonkers, Yonkers

Vključevanje udeležencevFaza 3

Starost 18–70 · Vsi spoli · Posodobljeno 24. sep. 2026 · NCT06937086

A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes

NYC Research INC, Long Island City

Vključevanje udeležencevFaza 3

Starost 18 in več · Vsi spoli · Posodobljeno 22. sep. 2026 · NCT07282600

A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin

NYU Langone Health, New York
Weill Cornell Medical College, New York
IMA Clinical Research Manhattan, New York

Vključevanje udeležencevFaza 3

Starost 18 in več · Vsi spoli · Posodobljeno 22. sep. 2026 · NCT07392190

A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight

Rochester Clinical Research - Buffalo, Buffalo

Vključevanje udeležencevFaza 3

Starost 18 in več · Vsi spoli · Posodobljeno 22. sep. 2026 · NCT07369011

Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

Velocity Clinical Research - Binghamton, Binghamton
Hudson Valley Cardiovascular Practice PC, Poughkeepsie
Rochester Clinical Research, Rochester
in še 2

Vključevanje udeležencevFaza 3

Starost 45–99 · Vsi spoli · Posodobljeno 22. sep. 2026 · NCT07037433

A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes

Rochester Clinical Research, LLC, Rochester

Vključevanje udeležencevFaza 3

Starost 18 in več · Vsi spoli · Posodobljeno 22. sep. 2026 · NCT07321886

Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight

Ellipsis Research Group - Brooklyn - 7th Street, Brooklyn
Rochester Clinical Research - Buffalo, Buffalo
NYC Research INC, Long Island City
in še 1

Vključevanje udeležencevFaza 3

Starost 18 in več · Vsi spoli · Posodobljeno 22. sep. 2026 · NCT07353931

A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight

Dent Neurologic Institute, Amherst
Rochester Clinical Research, LLC, Rochester

Vključevanje udeležencevFaza 2

Starost 18–75 · Vsi spoli · Posodobljeno 22. sep. 2026 · NCT07589608

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

AURORA-1 Clinical Site, New Windsor

Vključevanje udeležencevFaza 3

Starost 18 in več · Vsi spoli · Posodobljeno 16. sep. 2026 · NCT07743463

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes

AURORA-2 Clinical Site, East Northport
AURORA-2 Clinical Site, East Syracuse
AURORA-2 Clinical Site, New Windsor

Vključevanje udeležencevFaza 3

Starost 18 in več · Vsi spoli · Posodobljeno 16. sep. 2026 · NCT07743450

A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide

NYC Research INC, Long Island City
Richmond University Medical Center, Staten Island
Southgate Medical Group, West Seneca

Vključevanje udeležencevFaza 2

Starost 18–75 · Vsi spoli · Posodobljeno 14. sep. 2026 · NCT06897475

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes

Rochester Clinical Research, Buffalo

Vključevanje udeležencevFaza 3

Starost 18 in več · Vsi spoli · Posodobljeno 14. sep. 2026 · NCT07351045

AMAZE 3: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea

Weil Cornell Medicine, New York

Vključevanje udeležencevFaza 3

Starost 18 in več · Vsi spoli · Posodobljeno 11. sep. 2026 · NCT07571005

A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)

ACCOMPLISH-2 Research Site, Albany
ACCOMPLISH-2 Research Site, Albany
ACCOMPLISH-2 Research Site, Brooklyn
in še 1

Vključevanje udeležencevFaza 3Vabljeni zdravi prostovoljci

Starost 18–79 · Vsi spoli · Posodobljeno 11. sep. 2026 · NCT07654374

AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea

Weil Cornell Medicine, New York

Vključevanje udeležencevFaza 3

Starost 18 in več · Vsi spoli · Posodobljeno 9. sep. 2026 · NCT07571109

A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

Dent Neurologic Institute, Amherst
Velocity Clinical Research, Syracuse, East Syracuse
Rochester Clinical Research, LLC, Rochester

Vključevanje udeležencevFaza 2

Starost 18–75 · Vsi spoli · Posodobljeno 8. sep. 2026 · NCT06143956

A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)

Equity Medical, New York

Vključevanje udeležencevFaza 4

Starost 18 in več · Vsi spoli · Posodobljeno 4. sep. 2026 · NCT06857942

Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes

Kailera Clinical Site, Albany
Kailera Clinical Site, Laurelton
Kailera Clinical Site, New York

Vključevanje udeležencevFaza 3

Starost 18 in več · Vsi spoli · Posodobljeno 3. sep. 2026 · NCT07284901

Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)

Velocity Clinical Research- Binghamton, Binghamton
Rochester Clinical Research, Rochester

Vključevanje udeležencevFaza 3

Starost 18–99 · Vsi spoli · Posodobljeno 3. sep. 2026 · NCT07684235

Alpelisib Challenge Test (ACT)

Columbia University Irving Medical Center, New York

Vključevanje udeležencevFaza 1Vabljeni zdravi prostovoljci

Starost 18–70 · Vsi spoli · Posodobljeno 3. sep. 2026 · NCT07778524

Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes

Kailera Clinical Site, Rochester

Vključevanje udeležencevFaza 3

Starost 18 in več · Vsi spoli · Posodobljeno 3. sep. 2026 · NCT07284875

Taxi ROADmAP (Realizing Optimization Around Diet And Physical Activity)

Mexican Consulate's Ventanilla de Salud (VDS), New York

Vključevanje udeležencevFaza 2Vabljeni zdravi prostovoljci

Starost 21 in več · Vsi spoli · Posodobljeno 2. sep. 2026 · NCT05770570

Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)

Icahn School of Medicine at Mount Sinai, New York
Rochester Clinical Research, Rochester

Vključevanje udeležencevFaza 3

Starost 18–99 · Vsi spoli · Posodobljeno 27. avg. 2026 · NCT07575399

A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus

Research Site, Cortland

Vključevanje udeležencevFaza 3

Starost 18 in več · Vsi spoli · Posodobljeno 25. avg. 2026 · NCT07784725

Human Models of Selective Insulin Resistance: Alpelisib, Part I

Columbia University Irving Medical Center, New York

Vključevanje udeležencevFaza 1Vabljeni zdravi prostovoljci

Starost 18–70 · Vsi spoli · Posodobljeno 24. avg. 2026 · NCT06354088

AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain

NYU Langone Orthopedic Center, New York
Hospital For Special Surgery, New York

Vključevanje udeležencevFaza 3

Starost 18 in več · Vsi spoli · Posodobljeno 17. avg. 2026 · NCT07509307

Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)

ACCOMPLISH-1 Research Site, Albany
ACCOMPLISH-1 Research Site, Brooklyn

Vključevanje udeležencevFaza 3

Starost 18–79 · Vsi spoli · Posodobljeno 10. avg. 2026 · NCT07654361

Vir: ClinicalTrials.gov, podatki pridobljeni 5. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.